Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Kallyope progresses to Phase 2, pioneering an oral treatment strategy for both obesity and Type 2 Diabetes
Latest Hotspot
3 min read
Kallyope progresses to Phase 2, pioneering an oral treatment strategy for both obesity and Type 2 Diabetes
8 October 2023
Kallyope, Inc. has commenced its Phase 2 experiment to assess K-757 and K-833.
Read →
Unleashing the Power of Inclisiran: A Comprehensive Review on R&D Breakthroughs, Action Mechanisms, and Drug Target
Drug Insights
4 min read
Unleashing the Power of Inclisiran: A Comprehensive Review on R&D Breakthroughs, Action Mechanisms, and Drug Target
8 October 2023
This article summarized the latest R&D progress of Inclisiran, the Mechanism of Action for Inclisiran, and the drug target R&D trends for Inclisiran.
Read →
New research shows Longhorn Vaccines and Diagnostics' Universal Flu Vaccine, LHNVD-105, triggers strong, durable immunity in lab animals
Latest Hotspot
3 min read
New research shows Longhorn Vaccines and Diagnostics' Universal Flu Vaccine, LHNVD-105, triggers strong, durable immunity in lab animals
8 October 2023
A new research indicates that Longhorn Vaccines and Diagnostics' Universal Flu Vaccine, LHNVD-105, elicits robust and long-lasting immunity in lab animals.
Read →
 A Comprehensive Review of Heparin sodium's R&D Innovations and Drug Target Mechanism
Drug Insights
4 min read
A Comprehensive Review of Heparin sodium's R&D Innovations and Drug Target Mechanism
8 October 2023
This article summarized the latest R&D progress of Heparin sodium, the Mechanism of Action for Heparin sodium, and the drug target R&D trends for Heparin sodium.
Read →
U.S. FDA Approves Takeda's ENTYVIO (vedolizumab) for continued treatment of severe active Ulcerative Colitis via under-the-skin injection
Latest Hotspot
3 min read
U.S. FDA Approves Takeda's ENTYVIO (vedolizumab) for continued treatment of severe active Ulcerative Colitis via under-the-skin injection
8 October 2023
Takeda announced U.S. FDA approval for ENTYVIO®(vedolizumab) subcutaneous delivery as a maintenance treatment for moderate to severe ulcerative colitis in adults, after initial intravenous therapy.
Read →
 Pharmaceutical Insights: Granisetron's R&D Progress and its Mechanism of Action on Drug Target
Drug Insights
4 min read
Pharmaceutical Insights: Granisetron's R&D Progress and its Mechanism of Action on Drug Target
8 October 2023
This article summarized the latest R&D progress of Granisetron, the Mechanism of Action for Granisetron, and the drug target R&D trends for Granisetron.
Read →
Initial Recipient of Omisirge™ (omidubicel-onlv) by Gamida Cell Administered to First Patient
Latest Hotspot
3 min read
Initial Recipient of Omisirge™ (omidubicel-onlv) by Gamida Cell Administered to First Patient
8 October 2023
Gamida Cell Ltd. has declared that the initial patient has been subjected to a stem cell transplantation procedure using Omisirge (omidubicel-onlv).
Read →
Exploring Gliclazide's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
Drug Insights
4 min read
Exploring Gliclazide's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
8 October 2023
This article summarized the latest R&D progress of Gliclazide, the Mechanism of Action for Gliclazide, and the drug target R&D trends for Gliclazide.
Read →
Abeona Therapeutics has requested a U.S. FDA Biologics License for expedited review of EB-101, a treatment for Recessive Dystrophic Epidermolysis Bullosa patients
Latest Hotspot
4 min read
Abeona Therapeutics has requested a U.S. FDA Biologics License for expedited review of EB-101, a treatment for Recessive Dystrophic Epidermolysis Bullosa patients
8 October 2023
Abeona Therapeutics Inc. has reported that they've lodged a BLA with U.S. FDA with a request to endorse EB-101.
Read →
Decoding Fosfomycin tromethamine: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
Drug Insights
4 min read
Decoding Fosfomycin tromethamine: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
8 October 2023
This article summarized the latest R&D progress of Fosfomycin tromethamine, the Mechanism of Action for Fosfomycin tromethamine, and the drug target R&D trends for Fosfomycin tromethamine.
Read →
AltruBio declares FDA approval on IND submission for ALTB-268, an Immune Checkpoint Booster, triggering a Phase 2 Clinical Study for dealing with Ulcerative Colitis
Latest Hotspot
3 min read
AltruBio declares FDA approval on IND submission for ALTB-268, an Immune Checkpoint Booster, triggering a Phase 2 Clinical Study for dealing with Ulcerative Colitis
8 October 2023
The US FDA approved AltruBio Inc.'s IND request, allowing Phase 2 clinical trials to start for its immune checkpoint booster, ALTB-268, for ulcerative colitis.
Read →
Deep Scientific Insights on Lanthanum carbonate's R&D Progress, Mechanism of Action, and Drug Target
Drug Insights
4 min read
Deep Scientific Insights on Lanthanum carbonate's R&D Progress, Mechanism of Action, and Drug Target
8 October 2023
This article summarized the latest R&D progress of Lanthanum carbonate, the Mechanism of Action for Lanthanum carbonate, and the drug target R&D trends for Lanthanum carbonate.
Read →